![]() The participants included 33 medical doctors (66%), 1 nurse (2%), 11 laboratory technicians (22%), and 5 administrative laboratory officers (10%). Nineteen participants (38%) had a history of other comorbidities such as obesity, hypertension, and hypercholesterolemia. The participants included 31 women (62%) and 19 men (38%) aged 25–57 years. This study monitors time-dependent changes in anti-S-RBD IgG antibody levels on day 0, one day before vaccination (first dose), compared with antibody levels on days 14, 28, 90, and 180 (after the second dose). There are limited studies on long-term immunity and minimal data to evaluate SARS-CoV-2 anti-S-RBD IgG antibody levels in vaccinated healthcare workers, especially in Indonesia. Recent studies have reported a rapid decrease in antibodies following SARS-CoV-2 infection 13. Phases I and II COVID-19 vaccine trials are based on the magnitude of the neutralizing antibody response and SARS-CoV-2 anti-spike protein receptor-binding domain (anti-S-RBD) immunoglobulin G (IgG) titer 12. Different vaccine platforms are available and under evaluation for SARS-CoV-2, including virus-vectored vaccines, protein subunit vaccines, genetic vaccines, and monoclonal antibodies for passive immunization, each with distinct benefits and drawbacks 5, 11. Production of S-protein-neutralizing antibodies in vaccinated subjects is the primary aim of all COVID-19 vaccines. Healthcare workers and other front liners were vaccinated simultaneously after issuing EUA permission from the Indonesian Food and Drug Supervisory Agency 9.Īlmost all vaccines rely on antibody responses, neutralizing antibodies to prevent virions from infiltrating target cells, thus blocking replication 10. In Indonesia, vaccination began on 13 January 2021. Countries prioritize vaccinating healthcare workers against COVID-19 because they are exposed to the virus while working 8. Healthcare workers are the group most affected by the COVID-19 pandemic. The degree and duration of protection against infection and reinfection remain unclear 7. Phase 3 trials indicated that the efficacy rate remained high 14 days after the second dose, although it varied from 51 to 84% in Brazil, Chile, and Turkey. Phase 2 clinical trials in China reported 97% seroconversion 28 days after administration of the CoronaVac vaccine 6. The CoronaVac vaccine is given in two doses the second dose is recommended 14 days after the first dose. The CoronaVac vaccine produced by Sinovac Life Sciences (Beijing, China) uses conventional inactivation techniques to generate an immune response against all viral proteins, including matrix, envelope, nucleoprotein structure, and SARS-CoV-2 spike proteins 4, 5. The Indonesian Food and Drug Supervisory Agency has issued an Emergency Use Authorization (EUA) for five commercial COVID-19 vaccine products, including CoronaVac produced by Bio Farma, Pfizer, AstraZeneca, Moderna, and Zifivax 3. Real-life data continue to demonstrate the effects of community vaccination in breaking the transmission chain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 2. ![]() Vaccination has been crucial in preventing asymptomatic infections. The coronavirus disease 2019 (COVID-19) pandemic has affected many, magnifying global socioeconomic and health inequalities 1. Vaccinated individuals are still at risk of being infected by SARS-CoV-2 after day 90.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |